IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sanyog m. Pendharkar et. al.

Serial No. : Art Unit:

Filed: January 30, 2004 Examiner:

For : HEMOSTATIC COMPOSITIONS AND DEVICES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 30, 2004
(Date of Deposit)

William K. Wissing
(Name of applicant, assignee, or Registered Representative)

(Signature)

January 30, 2004

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FIRST INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

to the examination of the present patent application does not exist. In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required. In accordance with \$1.129(a), this Information Disclosure Statement is being filed in connection with \square the first or _second After Final Submission, therefore: Statement in Accordance with \$1.97(e) (attached); or \Box Please charge Deposit Account No. 10-0750/ the fee of \$180.00 as set forth in / \$1.17(p). In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: Statement in Accordance with §1.97(e) (attached); or

This statement should not be construed as a representation

that a search has been made, or that information more material

Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth in
§1.17(p).
In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with \$1.97(e) as set forth below and the fee of \$180.00 as set forth in \$1.17(p). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
1449 are enclosed herewith EXCEPT THAT:
1145 die enclosed helewich Except THAT:
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
☐ Copies of only foreign patent documents and non-patent
literature are enclosed in accordance with 37 CFR 1.98 (a)(2).
(The U.S. patents and each U.S. patent application publication
listed on the attached Form PTO-1449 are not enclosed because
this U.S. patent application was filed after June 30, 2003 or
this international application has entered the national stage

under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i). There are no listed references which are not in the English language. The relevance of those listed references which are not in the English language is as follows: X Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ETH 5084/WKW. This form is submitted in triplicate. Respectfully submitted, William K. Wissing Reg. No. 34,757 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-6201

DATED: January 30,2004

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute	for	form '	1449	APT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

a concessi of anominator anioso a ampayo	d talle only territori
Application Number	
Filing D te	January 30, 2004
First Named Inventor	Sanyog M. P ndharkar et. al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ETH-5084-NP

		U.S. Patent Document		ment			D O.b Lines
Examiner Initials		Cite	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		2,507,244		John T. Correll et. al.	05/09/1950		
		5,733,572		Evan C. Unger et. al.	03/31/1998		
		5,908,054		Jason H. Safabash et. al.	06/01/1999		
		6,045,570		Gordon H. Epstein et. al.	04/04/2000		
		6,063,061		Donald G. Wallace et. al.	05/16/2000		
		6,066,325		Donald G. Wallace et. al	05/23/2000		
		2002/0193448		Donald G. Wallace et. al	12/19/2002		
		2003/0064109		Zhen Qian et. al.	04/03/2003		

				FOR	EIGN PATENT DOCUMENTS			
	Cite	Foreign Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant		
Examiner Initials			Office ³	Number⁴ K	indCode⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear
		EP	0740528	B1	EP	11/30/1994		
		wo	98/08550	A1	PCT	03/05/1998		
		wo	00/76533	A1	PCT	12/12/2000		
		wo	01/97826	A2	PCT	12/27/2001		
		wo	01/97873	A2	PCT	12/27/2001		
		wo	02/072128	A1	PCT	09/19/2002		
•		wo	03/007845	A1	PCT	01/30/2003		
-		EP	0927053	B1	EP	04/02/2003		
	Ī	wo	03/055531	A2	PCT	07/10/2003		

Examiner	Date		
Signature	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a conscion of anominator ances a ampayer	
Application Numb r	
Filing Date	January 30, 2004
First N med Inventor	Sanyog M. Pendharkar et. al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ETH5084

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Lock to name of the cuther (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	T ²
Examiner's Initials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
made	.,,,,	Sakurahayashi "Clinical Evaluation of New Hemostatic Agent for Hemostasis	
		from Biopsy Wounds in the Liver" Gastroenterological Endoscopy, Vol. 30(10),	
·		(Oct. 1988) pp. 2256	
·			
			L
	 		
	 		
	\vdash		
			-
	<u> </u>		
			ļ
			
_	+-		
			
	+		
	 		<u>L</u>

	Date
Examiner	Considered
Signature	Considered
Ogracus	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.